Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia

Bone Marrow Transplantation
M LawlerS R McCann

Abstract

Allogeneic blood or bone marrow transplantation is a successful treatment for leukaemia and severe aplastic anaemia (SAA). Graft rejection following transplantation for leukaemia is a rare event but leukaemic relapse may occur at varying rates, depending upon the stage of leukaemia at which the transplant was undertaken and the type of leukaemia. Relapse is generally assumed to occur in residual host cells, which are refractory to, or escape from the myeloablative conditioning therapy. Rare cases have been described, however, in which the leukaemia recurs in cells of donor origin. Lack of a successful outcome of blood or bone marrow transplantation for severe aplastic anaemia (SAA), however, is due to late graft rejection or graft-versus-host disease. Leukaemia in cells of donor origin has rarely been reported in patients following allogeneic bone marrow transplantation for SAA. This report describes leukaemic transformation in donor cells following a second allogeneic BMT for severe aplastic anaemia. PCR of short tandem repeats in bone marrow aspirates and in colonies derived from BFUE and CFU-GM indicated the donor origin of leukaemia. Donor leukaemia is a rare event following transplantation for severe aplastic anaemia but m...Continue Reading

References

Apr 19, 1979·The New England Journal of Medicine·T C GossettC R Taylor
Jan 1, 1979·Medicine·D A Casciato, J L Scott
Sep 5, 1991·The New England Journal of Medicine·P V BrowneS R McCann
Sep 21, 1989·The New England Journal of Medicine·R P WitherspoonR Storb
May 1, 1986·British Journal of Haematology·H G KlingemannE D Thomas
Jul 1, 1985·British Journal of Haematology·J L SmithA J Provisor
Mar 1, 1984·Cancer Treatment Reviews·K Rieche
Mar 19, 1981·The New England Journal of Medicine·P E NewburgerR J O'Reilly

❮ Previous
Next ❯

Citations

Jul 18, 2012·Cell Biochemistry and Biophysics·Julio Roberto Cáceres-Cortés
Jul 14, 2016·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Prabhu ManivannanManoranjan Mahapatra
Mar 20, 2010·Stem Cell Reviews and Reports·Sergey V AnisimovAna S Correia
Apr 18, 2003·Cancer Genetics and Cytogenetics·Irén HaltrichGyörgy Fekete
Feb 28, 2007·Leukemia & Lymphoma·Guillermo J Ruiz-ArgüellesJavier Garcés-Eisele
Dec 10, 2008·Expert Opinion on Biological Therapy·Aravind Ramakrishnan, H Joachim Deeg
Oct 19, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel H Wiseman
Jan 9, 2003·The Journal of Laboratory and Clinical Medicine·Steven M DevineJohn F DiPersio
Nov 30, 2006·Blood·Catherine M Flynn, Dan S Kaufman
Mar 10, 2021·Bone Marrow Transplantation·Lacey WilliamsCatherine Lai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.